Top Markets
#1 Official Trump Official Trump +51.60%
#2 Movement Movement +32.33%
#3 Mubarak Mubarak +26.27%
#4 Pearl Pearl +24.49%
#5 Zama Zama +24.44%
#6 Melania Meme Melania Meme +22.38%
#7 EXOD EXOD +18.93%
#8 Wrapped POL Wrapped POL +18.74%
#9 POL (ex-MATIC) POL (ex-MATIC) +18.66%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +16.92%
Coin of the day
Official Trump Official Trump
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Citius Oncology, Inc. Citius Oncology, Inc.

Citius Oncology, Inc.

CTOR
Kedudukan dalam Saham #23802
Citius Oncology, Inc. concentrates on advancing innovative, targeted... Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Harga Saham
$0.7426
Disegerakkan terakhir: 2026-08-21
Modal Pasaran
$69.05M
Perubahan (1 hari)
-2.17%
Perubahan (1 tahun)
-57.57%
Negara
US
Perdagangan Citius Oncology, Inc. (CTOR)

Kategori

Healthcare
Sejarah hasil dividen untuk Citius Oncology, Inc. (CTOR)
Hasil dividen (TTM) bagi Citius Oncology, Inc. (simbol saham: CTOR) pada 2026 adalah: 0
Purata hasil dividen 5 tahun terakhir: 0.00%
Sejarah hasil dividen untuk Citius Oncology, Inc. (CTOR) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil dividen (TTM) untuk syarikat serupa atau pesaing
Syarikat Hasil Dividen Negara
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
0.57%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
2.01%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
2.74%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
2.69%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
2.47%
US